Merriman Curhan Ford Reiterates a 'Buy' on Regeneron (REGN); Raising Target Range
More News related to REGN
- Regeneron Announces Presentation at the 21st Annual Piper Jaffray Healthcare Conference
- Merriman Curhan Ford Reiterates a 'Buy' on Regeneron (REGN); Raising Target Range
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Regeneron Announces Conference Call to Discuss Expanded Antibody Collaboration with Sanofi-aventis
More News related to Analyst Comments
- Clarient (CLRT) GIven Exclusive Rights to Develop and Commercialize MUC1 Protein
- Rovi (ROVI) Patents Infringed by Virgin Media
Merriman Curhan Ford reiterates a 'Buy' rating on Regeneron (Nasdaq: REGN), raising target range to $34-35 from $29-31.
Merriman analyst says, "Regeneron is developing a proprietary set of “antibody-like” compounds called “traps” that can target signaling molecules with distinct implication in multiple diseases. In our view, Regeneron is an exciting biopharmaceutical development story based primarily on its first product on the market, late-stage product candidates and strong partners. The company has premier science being translated into clinically viable candidates and a strong management team. We believe Regeneron represents a core long-term biotech portfolio holding."
To see more analyst ratings on REGN Click Here.
Related Categories
Analyst CommentsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
